ALK, ROS1 and RET fusions in 1139 lung adenocarcinomas: A comprehensive study of common and fusion pattern-specific clinicopathologic, histologic and cytologic features

Lung Cancer

Volumn 84, Issue 2, 2014, Pages 121-126

  Pan, Yunjian ^a,b   Zhang, Yang ^a,b   Li, Yuan ^a,b   Hu, Haichuan ^a,b   Wang, Lei ^a,b   Li, Hang ^a,b   Wang, Rui ^a,b   Ye, Ting ^a,b   Luo, Xiaoyang ^a,b   Zhang, Yiliang ^a,b   Li, Bin ^a,b   Cai, Deng ^a,b   Shen, Lei ^a,b   Sun, Yihua ^a,b   Chen, Haiquan ^a,b  

^a FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^b FUDAN UNIVERSITY   (China)

Author keywords

ALK fusions; Cytomorphology; Histology; Lung adenocarcinoma; RET fusions; ROS1 fusions

Indexed keywords

MUCIN; ANAPLASTIC LYMPHOMA KINASE; B RAF KINASE; BRAF PROTEIN, HUMAN; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; KRAS PROTEIN, HUMAN; ONCOPROTEIN; PROTEIN RET; PROTEIN TYROSINE KINASE; RAS PROTEIN; RET PROTEIN, HUMAN; ROS1 PROTEIN, HUMAN;

ADULT; ALK GENE; ARTICLE; BRAF GENE; CANCER PATIENT; CANCER SIZE; CELL STRUCTURE; CHINESE; CYTOLOGY; EGFR GENE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FUSION GENE; GENE MUTATION; GENETIC SCREENING; HISTOLOGY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; ONCOGENE; ONCOGENE K RAS; ONCOGENE NEU; OVERALL SURVIVAL; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RECURRENCE FREE SURVIVAL; RET GENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; ROS1 GENE; SOLID TUMOR; ADENOCARCINOMA; DISEASE FREE SURVIVAL; GENETICS; KAPLAN MEIER METHOD; LUNG TUMOR; MIDDLE AGED; MORTALITY; NUCLEOTIDE SEQUENCE; PATHOLOGY;

ADENOCARCINOMA; DISEASE-FREE SURVIVAL; DNA MUTATIONAL ANALYSIS; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; ONCOGENE PROTEINS, FUSION; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS C-RET; RAS PROTEINS; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2;

EID: 84899471648     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2014.02.007     Document Type: Article

References (19)

1. Soda M., Choi Y.L., Enomoto M., Takada S., Yamashita Y., Ishikawa S., et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007, 448:561-566.
2. Takeuchi K., Soda M., Togashi Y., Suzuki R., Sakata S., Hatano S., et al. RET, ROS1 and ALK fusions in lung cancer. Nat Med 2012, 18:378-381.
3. Sun Y., Ren Y., Fang Z., Li C., Fang R., Gao B., et al. Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases. J Clin Oncol 2010, 28:4616-4620.
4. Shaw A.T., Kim D.W., Nakagawa K., Seto T., Crino L., Ahn M.J., et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 2013, 368:2385-2394.
5. Li C., Fang R., Sun Y., Han X., Li F., Gao B., et al. Spectrum of oncogenic driver mutations in lung adenocarcinomas from East Asian never smokers. PLoS One 2011, 6:e28204.
6. Bergethon K., Shaw A.T., Ou S.H., Katayama R., Lovly C.M., McDonald N.T., et al. ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol 2012, 30:863-870.
7. Kohno T., Ichikawa H., Totoki Y., Yasuda K., Hiramoto M., Nammo T., et al. KIF5B-RET fusions in lung adenocarcinoma. Nat Med 2012, 18:375-377.
8. Lipson D., Capelletti M., Yelensky R., Otto G., Parker A., Jarosz M., et al. Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies. Nat Med 2012, 18:382-384.
9. Wang R., Hu H., Pan Y., Li Y., Ye T., Li C., et al. RET fusions define a unique molecular and clinicopathologic subtype of non-small-cell lung cancer. J Clin Oncol 2012, 30:4352-4359.
10. Ju Y.S., Lee W.C., Shin J.Y., Lee S., Bleazard T., Won J.K., et al. A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing. Genome Res 2012, 22:436-445.
11. Travis W.D., Brambilla E., Noguchi M., Nicholson A.G., Geisinger K.R., Yatabe Y., et al. International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 2011, 6:244-285.
12. Wang R., Pan Y., Li C., Hu H., Zhang Y., Li H., et al. The use of quantitative real-time reverse transcriptase PCR for 5' and 3' portions of ALK transcripts to detect ALK rearrangements in lung cancers. Clin Cancer Res 2012, 18:4725-4732.
13. Heinze G., Schemper M. A solution to the problem of separation in logistic regression. Stat Med 2002, 21:2409-2419.
14. Yoshida A., Kohno T., Tsuta K., Wakai S., Arai Y., Shimada Y., et al. ROS1-rearranged lung cancer: a clinicopathologic and molecular study of 15 surgical cases. Am J Surg Pathol 2013, 37:554-562.
15. Li H., Pan Y., Li Y., Li C., Wang R., Hu H., et al. Frequency of well-identified oncogenic driver mutations in lung adenocarcinoma of smokers varies with histological subtypes and graduated smoking dose. Lung Cancer 2013, 79:8-13.
16. Zhang Y., Sun Y., Pan Y., Li C., Shen L., Li Y., et al. Frequency of driver mutations in lung adenocarcinoma from female never-smokers varies with histologic subtypes and age at diagnosis. Clin Cancer Res 2012, 18:1947-1953.
17. Nishino M., Klepeis V.E., Yeap B.Y., Bergethon K., Morales-Oyarvide V., Dias-Santagata D., et al. Histologic and cytomorphologic features of ALK-rearranged lung adenocarcinomas. Mod Pathol 2012, 25:1462-1472.
18. Yoshida A., Tsuta K., Nakamura H., Kohno T., Takahashi F., Asamura H., et al. Comprehensive histologic analysis of ALK-rearranged lung carcinomas. Am J Surg Pathol 2011, 35:1226-1234.
19. Jokoji R., Yamasaki T., Minami S., Komuta K., Sakamaki Y., Takeuchi K., et al. Combination of morphological feature analysis and immunohistochemistry is useful for screening of EML4-ALK-positive lung adenocarcinoma. J Clin Pathol 2010, 63:1066-1070.